Related Experiment Video

Updated: May 28, 2026

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma

Bruce D Cheson1, Nancy L Bartlett, Julie M Vose

  • 1Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA. bdc4@georgetown.edu

Cancer
|October 19, 2011
PubMed
Abstract

Insights

YM155 showed limited efficacy as a single agent for refractory diffuse large B-cell lymphoma (DLBCL). While well-tolerated, further research is needed, potentially in combination therapies.

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • Refractory diffuse large B-cell lymphoma (DLBCL) has limited treatment options.
  • YM155, a survivin suppressant, demonstrated prior activity in DLBCL.
  • This study evaluated YM155 in patients with refractory DLBCL.

Purpose of the Study:

  • To assess the efficacy of YM155 in patients with refractory DLBCL.
  • To characterize the toxicity profile of YM155 in this patient population.

Main Methods:

  • A phase II clinical trial involving 41 patients with refractory DLBCL.
  • Patients received YM155 at a dose of 5 mg/m²/day via continuous infusion for 168 hours every 21 days.
  • Treatment continued for up to 15 cycles, with a median of 3 cycles completed.

Main Results:

  • One patient achieved a complete remission (2.4%); 2 additional patients responded (5.9%).
  • Median progression-free survival was 58 days.
  • YM155 was generally well-tolerated, with anemia and fatigue as primary toxicities.

Conclusions:

  • YM155 demonstrated limited single-agent activity in refractory DLBCL.
  • Preclinical data suggest potential combination therapy with agents like rituximab.
  • A combination study of YM155 and rituximab is currently underway.

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...